$-0.09 EPS Expected for Pluristem Therapeutics Inc. (PSTI)

May 9, 2018 - By Migdalia James

Pluristem Therapeutics Inc. (NASDAQ:PSTI) LogoInvestors sentiment decreased to 1.67 in 2017 Q4. Its down 0.83, from 2.5 in 2017Q3. It turned negative, as 3 investors sold Pluristem Therapeutics Inc. shares while 6 reduced holdings. 7 funds opened positions while 8 raised stakes. 3.73 million shares or 0.16% less from 3.73 million shares in 2017Q3 were reported.
Virtu Fincl Ltd Co invested 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Hightower Limited Liability has 0% invested in Pluristem Therapeutics Inc. (NASDAQ:PSTI). 126,473 are held by Psagot House Ltd. Geode Capital Mngmt Ltd reported 41,630 shares. Menora Mivtachim Ltd holds 0.05% or 1.00M shares in its portfolio. Morgan Stanley reported 5,326 shares stake. Raymond James And Associate invested 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Focused Wealth Mgmt Incorporated reported 10,000 shares. Retail Bank Of New York Mellon Corp has invested 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Van Eck Associate Corporation invested 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Noven Financial Grp Inc Inc holds 12,000 shares. Two Sigma Ltd Liability Co accumulated 40,302 shares. Susquehanna Group Inc Inc Llp, Pennsylvania-based fund reported 171,040 shares. 17,525 are held by State Street. Jane Street Gp Lc invested 0% of its portfolio in Pluristem Therapeutics Inc. (NASDAQ:PSTI).

Analysts expect Pluristem Therapeutics Inc. (NASDAQ:PSTI) to report $-0.09 EPS on May, 14.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.09 EPS. The stock decreased 0.75% or $0.01 during the last trading session, reaching $1.33. About 139,921 shares traded. Pluristem Therapeutics Inc. (NASDAQ:PSTI) has risen 13.45% since May 10, 2017 and is uptrending. It has outperformed by 1.90% the S&P500.

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics firm in Israel. The company has market cap of $147.45 million. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. It currently has negative earnings. The firm develops PLacental eXpanded cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.

More important recent Pluristem Therapeutics Inc. (NASDAQ:PSTI) news were published by: Nasdaq.com which released: “Mid-Morning Market Update: Markets Open Higher; Sprint And T-Mobile To Merge In $26 Billion Deal” on April 30, 2018, also Streetinsider.com published article titled: “Pluristem Therapeutics (PSTI) Says US FDA Cleared its Phase III Study in Treatment of Muscle Injury Following Hip …”, Benzinga.com published: “FDA Clears New Drug Application For Pluristem’s PLX-R18; What’s Next?” on April 30, 2018. More interesting news about Pluristem Therapeutics Inc. (NASDAQ:PSTI) was released by: Globes.Co.Il and their article: “Innovation Authority set to bring pharma cos to Israel” with publication date: May 08, 2018.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: